Adverum Bio Ownership | Who Owns Adverum Bio?
Adverum Bio Ownership Summary
Adverum Bio is owned by 15.26% institutional investors, 11.67% insiders, and 73.07% retail investors. Versant venture management is the largest institutional shareholder, holding 3.08% of ADVM shares. Franklin Biotechnology Discv A(acc)USD is the top mutual fund, with 5.46% of its assets in Adverum Bio shares.
ADVM Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Adverum Bio | 15.26% | 11.67% | 73.07% |
Sector | Healthcare Stocks | 47.06% | 8.01% | 44.93% |
Industry | Biotech Stocks | 44.97% | 7.82% | 47.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Versant venture management | 506.82K | 3.08% | $3.48M |
Frazier life sciences management | - | - | - |
Tcg crossover management | - | - | - |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Versant venture management | 506.82K | 4.50% | $3.48M |
Frazier life sciences management | - | - | - |
Tcg crossover management | - | - | - |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Versant venture management | 506.82K | 4.50% | -1.00 |
Frazier life sciences management | - | - | -1.07M |
Tcg crossover management | - | - | -2.01M |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Tcg crossover management | - | - | -2.01M |
Frazier life sciences management | - | - | -1.07M |
Versant venture management | 506.82K | 4.50% | -1.00 |
Sold Out
Holder | Change |
---|---|
Frazier life sciences management | -1.07M |
Tcg crossover management | -2.01M |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Jun 30, 2024 | 2 | -33.33% | 2,515,161 | -29.83% | 15 | 1.22% | - | -100.00% | 1 | - |
Mar 31, 2024 | 3 | -95.31% | 3,584,406 | -94.42% | 35 | 0.88% | 2 | -90.91% | 1 | -93.75% |
Dec 31, 2023 | 64 | 1.59% | 64,234,984 | -1.62% | 63 | 1.51% | 22 | -15.38% | 16 | -20.00% |
Sep 30, 2023 | 63 | 6.78% | 65,292,881 | -0.55% | 64 | 1.51% | 26 | 23.81% | 20 | -13.04% |
Jun 30, 2023 | 59 | 3.51% | 65,656,238 | 4.68% | 65 | 1.67% | 21 | 16.67% | 23 | 21.05% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Franklin Biotechnology Discv A(acc)USD | 1.14M | 5.46% | - |
Franklin Biotechnology Discovery A | 624.74K | 3.00% | - |
Vanguard Total Stock Mkt Idx Inv | 586.25K | 2.82% | - |
iShares Russell 2000 ETF | 543.65K | 2.61% | -1.22K |
Vanguard Institutional Extnd Mkt Idx Tr | 285.80K | 1.37% | - |
Fidelity Small Cap Index | 211.58K | 1.02% | -4.89K |
Fidelity Select Biotechnology | 200.94K | 0.97% | -124.85K |
iShares Russell 2000 Value ETF | 192.62K | 0.93% | - |
CREF Stock R1 | 141.83K | 0.68% | - |
State St Russell Sm/Mid Cp® Indx NL Cl C | 96.13K | 0.46% | -4.30K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jul 30, 2024 | Leonard Braden Michael | - | Buy | $613.47K |
Jul 17, 2024 | Leonard Braden Michael | - | Buy | $1.05M |
Jul 18, 2024 | Leonard Braden Michael | - | Buy | $735.74K |
Feb 07, 2024 | Scopa James Paul | - | Buy | $135.00K |
Feb 07, 2024 | Lupher, Jr. Mark L. | - | Buy | $175.50K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2024 Q3 | 3 | - |
2024 Q2 | - | - |
2024 Q1 | 2 | - |
2023 Q4 | - | - |
2023 Q3 | - | 2 |
ADVM Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools